Form 4: Ligand Pharmaceuticals Director John W. Kozarich Reports Acquisition of Stock and Options

Director John W. Kozarich reports acquisition of Ligand Pharmaceuticals stock and options through board grant.

Summary

• On June 14, 2024, John W. Kozarich, a director of Ligand Pharmaceuticals, acquired 1,252 shares of common stock and 5,444 non-qualified stock options.
• The stock was acquired through restricted stock units (RSUs) granted by the Board of Directors.
• Each RSU represents a contingent right to receive one share of Ligand's common stock.
• The options have an exercise price of $80.06 and expire on June 14, 2034.
• Both the RSUs and options fully vest on the earlier of the next annual meeting of the company stockholders or the first anniversary of the grant date.
• Following the reported transactions, Kozarich beneficially owns 43,775 shares of common stock and 5,444 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of shares by a director can be seen as a positive sign, but it's a routine event.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs and stock options is contingent upon future events (annual meeting or first anniversary of grant date), indicating a continued alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates